TICKERNERD
Menu
CRNXCRNXHealthcare · Biotechnology

CRNX Stock Forecast: Crinetics Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$85
+0.11% on the day

The 14 Wall Street analysts covering Crinetics Pharmaceuticals, Inc. hold a median 12-month price target of $85 — +0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$9.0B
Ticker Nerd rank
74 / 100
Median analyst target
$85
Analysts covering
14
Revenue$25.1M+2336.3% y/y
Operating income−$132.5M
Net income−$120.9M
Free cash flow−$94.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.0%
1M
+1.3%
YTD
+82.1%
1Y
+174.2%
From 52W high
0.0%
From 52W low
+181.8%
$30
$85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Crinetics Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Revisions
82
Value
73
Growth
62
Accruals
62
Quality
58
Issuance
41
Volatility
28
Size
17

Momentum (100): The shares have been drifting up relative to others.

Volatility (28): The share price moves around a lot.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70$80$90Oct 25Jan 26Apr 26Jul 26CRNXHigh $90Median $85Low $85

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
1 Buy13 Hold0 Sell
Low $85Median $85High $90

The green dot is the last close — the median target sits +0.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
28 July 2026UBSDowngradeNeutral$55 → $85
8 July 2026Evercore ISI GroupDowngradeIn-Line$88 → $85
8 July 2026Evercore ISI GroupDowngradeIn-Line—
8 July 2026TD CowenDowngradeHold—
8 July 2026TD CowenDowngradeHold—
7 July 2026BairdMaintainsOutperform—
7 July 2026BairdMaintainsOutperform$62 → $85
7 July 2026Cantor FitzgeraldDowngradeNeutral—
7 July 2026Cantor FitzgeraldDowngradeNeutral—
7 July 2026HC Wainwright & Co.DowngradeNeutral—
7 July 2026HC Wainwright & Co.DowngradeNeutral$81 → $85
7 July 2026JefferiesDowngradeHold—
7 July 2026JefferiesDowngradeHold$55 → $85
7 July 2026Jones TradingDowngradeHold—
7 July 2026OppenheimerDowngradePerform—
7 July 2026OppenheimerDowngradePerform—
2 July 2026UBSInitiatesBuy—
2 July 2026UBSInitiatesBuy$55
15 June 2026HC Wainwright & Co.ReiteratesBuy—
11 June 2026CitizensReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Crinetics Pharmaceuticals, Inc. returned +174.2% against +19.6% for the S&P 500, dividends included.

CRNX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26CRNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Crinetics Pharmaceuticals, Inc. (CRNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−17.1×

Cheaper than 95% of US stocks

Price / sales
213.4×

Cheaper than 3% of US stocks

Price / book
7.5×

Cheaper than 14% of US stocks

EV / EBITDA
−14.4×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
2336.3%

Higher than 99% of US stocks

Earnings growth (YoY)
2336.3%

Higher than 99% of US stocks

Gross margin
99.4%

Higher than 99% of US stocks

Operating margin
−527.3%

Higher than 7% of US stocks

Net margin
86.0%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−42.4%

Higher than 23% of US stocks

Return on assets
−26.3%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Crinetics Pharmaceuticals, Inc. (CRNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Crinetics Pharmaceuticals, Inc. has a market value of $9.0B and an enterprise value of $7.8B.

  • Revenue in the twelve months to 30 June 2026: $42.2M. The latest quarter grew 2336.3% year on year.

  • Net income over the same four quarters: −$501.6M, a −1189.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−5.04.

  • Free cash flow in the twelve months to 30 June 2026: −$425.2M.

  • Shares outstanding: 105.8M.

  • Trailing P/E: −17.1×; forward P/E: −21.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Crinetics Pharmaceuticals, Inc. employs 437 people — $96K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

CRNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRNXCrinetics Pharmaceuticals, Inc.$9.0B
74
TGTXTG Therapeutics, Inc.$8.6B
67
PCVXVaxcyte, Inc.$8.9B
51
IMVTImmunovant, Inc.$8.9B
41
SYRESpyre Therapeutics, Inc.$9.2B
47
IBRXImmunityBio, Inc.$8.2B
48
IONSIonis Pharmaceuticals, Inc.$9.5B
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Crinetics Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRNX news & analysis

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Business Wire · 17 Aug 2026negative

Kahn Swick & Foti, LLC, along with former Louisiana Attorney General Charles C. Foti Jr., is investigating the proposed acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals, under which Crinetics shareholders would receive $85.00 in cash per share. The firm is examining whether the adequacy of the consideration and the sale process were fair to Crinetics shareholders.

Why it matters — The investigation could signal challenges or added uncertainty around the proposed Vertex acquisition and the $85.00-per-share consideration Crinetics shareholders would receive.

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 3 Aug 2026positive

Crinetics Pharmaceuticals reported a Q2 loss of $1.14 per share, narrower than the Zacks Consensus Estimate of a $1.23 loss and narrower than the $1.23 loss a year ago. The company also beat revenue estimates for the quarter.

Why it matters — A CRNX watcher would note that the quarterly loss came in better than analysts expected and on higher-than-forecast revenue, marking an improvement versus the prior-year period.

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 3 Aug 2026positive

Crinetics Pharmaceuticals reported its second quarter 2026 financial results and provided a business update in its latest earnings announcement. Announcements included a Vertex agreement to acquire Crinetics for a total equity value of approximately $10.0 billion, or roughly $8.8 billion net of estimated cash acquired.

Why it matters — CRNX watchers would care because the company is being acquired by Vertex in a deal valued at approximately $10.0 billion, a major corporate event that would change Crinetics' outlook and ownership.

FAQ

Frequently asked questions about CRNX stock

What is the CRNX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Crinetics Pharmaceuticals, Inc. have a median 12-month price target of $85, with estimates ranging from $85 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRNX stock a buy right now?

Of the 14 analysts covering Crinetics Pharmaceuticals, Inc., 1 rate it a Buy, 13 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Crinetics Pharmaceuticals, Inc. 74 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRNX?

As at 22 Aug 2026, Crinetics Pharmaceuticals, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will CRNX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +0.3% from the last close, and Ticker Nerd's factor model ranks Crinetics Pharmaceuticals, Inc. 74 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRNX stock forecast for 2030?

No analyst covering Crinetics Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $90 over the next 12 months.

How has CRNX stock performed over the past year?

Crinetics Pharmaceuticals, Inc. returned +174.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Crinetics Pharmaceuticals, Inc. do?

Crinetics Pharmaceuticals Inc. is a global pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related tumors.

What is the latest news on CRNX?

The most recent item we track (Business Wire, 17 Aug 2026): "Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX". Kahn Swick & Foti, LLC, along with former Louisiana Attorney General Charles C. Foti Jr., is investigating the proposed acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals, under which Crinetics shareholders would receive $85.00 in cash per share. The firm is examining whether the adequacy of the consideration and the sale process were fair to Crinetics shareholders.

Company

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Inc. is a global pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related tumors. The company’s work centers on small-molecule medicines designed to address challenging hormone-driven conditions, with an emphasis on targeted treatments that can simplify care for patients. Its current portfolio includes a marketed therapy for acromegaly and a pipeline of investigational programs spanning disorders such as congenital adrenal hyperplasia, Cushing’s syndrome, neuroendocrine tumors, Graves’ disease, polycystic kidney disease, hyperparathyroidism, diabetes, and obesity. Crinetics Pharmaceuticals Inc. also applies its expertise in G-protein coupled receptor biology to support research across endocrine and oncology-related areas. Headquartered in San Diego, California, the company operates as a specialist in endocrine-focused drug discovery and commercialization.

CEO Dr. R. Scott Struthers Ph.D. · 437 employees · United States · https://www.crinetics.com